ORX142 Tablets
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Excessive Daytime Sleepiness
Conditions
Excessive Daytime Sleepiness
Trial Timeline
Jun 30, 2025 → Jun 15, 2026
NCT ID
NCT07082829About ORX142 Tablets
ORX142 Tablets is a phase 1 stage product being developed by Centessa Pharmaceuticals for Excessive Daytime Sleepiness. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07082829. Target conditions include Excessive Daytime Sleepiness.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07082829 | Phase 1 | Recruiting |
Competing Products
8 competing products in Excessive Daytime Sleepiness
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + PF-03654746 | Pfizer | Phase 2 | 51 |
| JZP-110 | Jazz Pharmaceuticals | Phase 2 | 49 |
| Solriamfetol + Placebo | Axsome Therapeutics | Approved | 82 |
| Solriamfetol 150 MG + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| Solriamfetol Oral Tablet + Placebo | Axsome Therapeutics | Approved | 82 |
| Fibrin Sealant Grifols + EVICEL | Grifols | Phase 3 | 74 |
| VSF-173 | Vanda Pharmaceuticals | Phase 2 | 44 |